



AIRFLOW 3
CLINICAL TRIAL

Are frequent COPD flare-ups keeping you down?

Find out if you qualify for a COPD research study

You may qualify for the AIRFLOW-3 Clinical Trial if:

- You have COPD and are taking daily medications to manage your symptoms
- Your COPD symptoms bother you frequently
- You have been hospitalized or have taken additional medications because of COPD flare-ups in the past year
- You are between 40 and 78 years old
- You are not currently a smoker, and will continue to not smoke

For additional eligibility requirements and information, contact a study representative below or visit www.airflowtrial.com

Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.

Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

V3, 15 July 2020; MCA-0131.A 0720